Romée J. A. L. M. Snijders

Romée J. A. L. M. Snijders

Auto-generated profile, based on publicly available information

Romée J. A. L. M. Snijders

Department of Gastroenterology and Hepatology, Radboudumc, Nijmegen, the Netherlands; European Reference Network on Hepatological Diseases (ERN RARE-LIVER)

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2023 in Journal of Hepatology
Verified
Journal Article
Open access
RSRomée J.A.L.M. Snijders
Romée J.A.L.M. Snijders
ASAnna E.C. Stoelinga
Anna E.C. Stoelinga
TGTom J.G. Gevers
Tom J.G. Gevers
SPSimon Pape
Simon Pape
MBMaaike Biewenga
Maaike Biewenga
JDJoost P.H. Drenth
Joost P.H. Drenth
Patients with autoimmune hepatitis (AIH) almost inevitably require lifelong immunosuppressive treatment. There is genuine concern about the efficacy and tolerability of the current standard combination therapy of prednisolone and azathioprine. Mycophenolate mofetil (MMF) has emerged as an alternative option. The aim of this study was to compare MMF to azathioprine as induction therapy. In this 24-week, prospective, randomised, open-label, multicentre superiority trial, 70 patients with treatment-naive AIH received either MMF or azathioprine, both in combination with prednisolone. The primary endpoint was biochemical remission defined as normalisation of serum levels of alanine aminotransferase and immunoglobulin G after 24 weeks of treatment. Secondary endpoints included safety and tolerability. Seventy patients (mean 57.9 years (standard deviation (SD) 14.0); 72.9% female) were randomly assigned to the MMF plus prednisolone (n=39) or azathioprine plus prednisolone (n=31) group. The primary endpoint was met in 56.4% and 29.0% of patients assigned to the MMF group and the azathioprine group, respectively (difference, 27.4 percentage points; 95% confidence interval (CI), 4.0 to 46.7; p=0.022). The MMF group exhibited higher complete biochemical response rates at 6 months (72.2% vs. 32.3%; p=0.004). No serious adverse events occurred in patients who received MMF (0%) but serious adverse events were reported in four patients who received azathioprine (12.9%) (p=0.034). Two patients in the MMF group (5.1%) and eight patients in the azathioprine group (25.8%) discontinued treatment owing to adverse events or serious adverse events (p=0.018). In patients with treatment-naive AIH, MMF with prednisolone achieved a significantly higher rate of biochemical remission at 24 weeks compared to azathioprine combined with prednisolone. Azathioprine use was associated with more (serious) adverse events leading to cessation of treatment, suggesting superior tolerability of MMF. This randomised controlled trial directly compares azathioprine and mycophenolate mofetil (MMF), both in combination with prednisolone, for the induction of biochemical remission in treatment-naive patients with autoimmune hepatitis (AIH). Achieving complete remission is desirable to prevent disease progression. Patients assigned to the MMF group reached biochemical remission more often and experienced fewer adverse events. The findings in this trial may contribute to the re-evaluation of international guidelines for the standard of care in treatment-naive patients with AIH. #NCT02900443.

22 April 2023 in JHEP Reports
Verified
Journal Article
Open access
KZKalliopi Zachou
Kalliopi Zachou
KAKalliopi Azariadis
Kalliopi Azariadis
Ellina LytvyakEllina Lytvyak
Ellina Lytvyak
RSRomée J.A.L.M. Snijders
Romée J.A.L.M. Snijders
ATAtsushi Takahashi
Atsushi Takahashi
GDGeorge Dalekos
George Dalekos
Non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) affect 17–46% of Western countries, making coexistence with other liver diseases inevitable. We investigated the prevalence and clinical significance of NAFLD/NASH or the components of metabolic syndrome (MetS) in a large multicentric cohort of patients with autoimmune hepatitis (AIH). Data from six academic centres (Greece, Canada, Japan, Germany, The Netherlands, and Spain) were evaluated. The presence of NAFLD/NASH in liver biopsy, MetS components, and clinical and laboratory parameters were recorded. A total of 640 patients (474 females, age 49 [4–87] years; follow-up 78 [1–521] months) were included. NAFLD was present in 146 (22.8%) patients (AIH/non-alcoholic fatty liver [NAFL] 115 [18%], AIH/NASH 31 [4.8%]). AIH/NAFL patients were older (p = 0.017), more frequently overweight or obese (p = 0.002), had hypertension (p = 0.001), and had diabetes (p = 0.016), whereas they less frequently had acute presentation (p = 0.002) and soluble liver antigen/liver pancreas positivity (p <0.05), lower transaminases (p <0.001), ALP (p = 0.028) and IgG (p = 0.004) and higher albumin (p <0.001) than patients with AIH only. Patients with AIH/NASH more frequently had cirrhosis at diagnosis (p = 0.036) and higher IgG (p = 0.009). Response to treatment did not differ between groups. Patients with cirrhosis with AIH/NAFL had higher frequency of decompensation compared with patients with AIH only (p <0.05). Patients with type 2 diabetes mellitus and dyslipidaemia had increased hazard of disease progression (p <0.05 for each). The prevalence of NAFLD in AIH is similar to the general population. Concurrence of NASH in patients with AIH signifies a more severe disease, whereas that of NAFL may indicate a worse prognosis in patients with cirrhosis. T2DM and dyslipidaemia in AIH patients are associated with dismal parameters of outcome. Our findings suggest that NAFLD presence or even components of MetS in patients with AIH may affect prognosis, so closer follow-up of such patients is warranted. Non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) affect many people, making coexistence with other liver diseases inevitable. We investigated the prevalence and clinical significance of NAFLD/NASH or the components of metabolic syndrome (MetS) in patients with autoimmune hepatitis (AIH). NAFLD and NASH presence in patients with AIH is as frequent as in the general population. The concurrence of NASH in patients with AIH seems to signify a more severe disease, whereas that of non-alcoholic fatty liver may indicate a worse prognosis in a specific subgroup of patients who already have cirrhosis at diagnosis. Diabetes or dyslipidaemia in patients with AIH were associated with worse prognosis. Therefore, it seems that closer follow-up of patients with concurrent AIH and NAFLD or AIH and components of MetS is needed.

10 April 2023 in Liver International
Verified
Journal Article
Open access
RSRomée J. A. L. M. Snijders
Romée J. A. L. M. Snijders
DADavid N. Assis
David N. Assis
YOYe H. Oo
Ye H. Oo
MSMarcial Sebode
Marcial Sebode
RTRichard Taubert
Richard Taubert
TRthe International Autoimmune Hepatitis Group (IAIHG) collaborators and the European Reference Network for Rare Liver Diseases (ERN RARE‐LIVER)
the International Autoimmune Hepatitis Group (IAIHG) collaborators and the European Reference Network for Rare Liver Diseases (ERN RARE‐LIVER)
Autoimmune hepatitis (AIH) is a rare autoimmune liver disease that is characterised by a chronic inflammatory immune reaction directed against hepatocytes. The disease results in a substantial reduction in quality of life and potentially leads to liver‐related complications or death. The International Autoimmune Hepatitis Group (IAIHG) initiated a series of research workshops to uncover the scientific gaps and opportunities in AIH. This review summarises the results of the latest workshop in Maastricht in 2022 and reviews the current challenges in adult AIH, particularly in relation to four important aspects of AIH: diagnostics; new immunomodulatory therapies; clinical trial design; and unmet clinical needs. This review also summarises the progress made since the AIH workshop in 2017. Patients and patient representatives were actively involved in the parallel working groups alongside clinicians and researchers. Despite 40 years of experience with diagnosing and treating AIH, false diagnoses occur and treatment is still based on nonselective immunosuppression. In addition to the need for more specific diagnostic tests, prognostic markers and tailor‐based treatments, a major unmet clinical need was identified in areas of care delivery and health‐related quality of life.

13 December 2022 in Trials
Verified
Journal Article
Open access
PDF file
RSRomée J. A. L. M. Snijders
Romée J. A. L. M. Snijders
ASAnna E. C. Stoelinga
Anna E. C. Stoelinga
TGTom J. G. Gevers
Tom J. G. Gevers
SPSimon Pape
Simon Pape
MBMaaike Biewenga
Maaike Biewenga
OGon behalf of the Dutch Autoimmune Hepatitis Working Group
on behalf of the Dutch Autoimmune Hepatitis Working Group
Background: Currently, the standard therapy for autoimmune hepatitis (AIH) consists of a combination of prednisolone and azathioprine. However, 15% of patients are intolerant to azathioprine which necessitates cessation of azathioprine or changes in therapy. In addition, not all patients achieve complete biochemical response (CR). Uncontrolled data indicate that mycophenolate mofetil (MMF) can induce CR in a majority of patients. Better understanding of first-line treatment and robust evidence from randomised clinical trials are needed. The aim of this study was to explore the potential benefits of MMF as compared to azathioprine, both combined with prednisolone, as induction therapy in a randomised controlled trial in patients with treatment-naive AIH. Methods: CAMARO is a randomised (1:1), open-label, parallel-group, multicentre superiority trial. All patients with AIH are screened for eligibility. Seventy adult patients with AIH from fourteen centres in the Netherlands and Belgium will be randomised to receive MMF or azathioprine. Both treatment arms will start with prednisolone as induction therapy. The primary outcome is biochemical remission, defined as serum levels of alanine aminotransferase and immunoglobulin G below the upper limit of normal. Secondary outcomes include safety and tolerability of MMF and azathioprine, time to remission, changes in Model For End-Stage Liver Disease (MELD)-score, adverse events, and aspects of quality of life. The study period will last for 24 weeks. Discussion: The CAMARO trial investigates whether treatment with MMF and prednisolone increases the proportion of patients in remission compared with azathioprine and prednisolone as the current standard treatment strategy. In addition, we reflect on the challenges of conducting a randomized trial in rare diseases. Trial registration: EudraCT 2016-001038-91. Prospectively registered on 18 April 2016. Graphical

17 August 2022 in Journal of Hepatology
Verified
Journal Article
Closed access
RSRomée J.A.L.M. Snijders
Romée J.A.L.M. Snijders
TGTom J.G. Gevers
Tom J.G. Gevers
MHMichael A. Heneghan
Michael A. Heneghan
JDJoost P.H. Drenth
Joost P.H. Drenth